Genomics Moves to the Front Line of Malaria Surveillance

Malaria molecular surveillance has moved from an experimental idea to a recognized pillar of the World Health Organization’s strategy for malaria control and elimination, and a new collection of studies published in Frontiers in Genetics shows just how quickly the field is maturing. The editorial convening the Research Topic, led by Shazia Ruybal-Pesántez of the Barcelona Institute for Global Health together with Johanna H. Kattenberg, Anita Ghansah, and Sarah Auburn, argues that parasite genotyping now underpins a growing set of surveillance use cases that align directly with the programmatic questions national malaria control and elimination programs must answer at every stage of the elimination pathway. What was once proof-of-concept science is becoming operational infrastructure.

The central promise of malaria molecular surveillance is deceptively simple: read the parasite’s genome and you can read the epidemic. Genetic data can reveal whether infections are imported or locally acquired, how transmission clusters shift across space and time, and whether drug-resistant lineages are quietly expanding. High-throughput sequencing, increasingly complemented by targeted and portable platforms, now makes it feasible to genotype parasites at the scale programs require, while a maturing analytical toolkit converts raw sequence data into epidemiologically meaningful signals. Yet the editors are candid about persistent obstacles: methods must be accessible, appropriately matched to the question at hand, and able to deliver actionable information to the program officers who need it.

A recurring barrier has been the cost, infrastructure, and specialist expertise that next-generation sequencing demands, which are often unavailable precisely where surveillance is most needed. Several contributions tackle this head-on by validating targeted approaches that recover information comparable to whole genome sequencing at a fraction of the cost. Niaré and colleagues present a highly multiplexed molecular inversion probe panel for Plasmodium falciparum that targets common single-nucleotide polymorphisms and approximates whole-genome-based assessments of selection and relatedness, effectively bringing genome-scale inference within reach of programmatic budgets. In a complementary evaluation, Cabrera-Sosa and colleagues benchmark newly developed SNP barcode panels for both P. falciparum and P. vivax against established microsatellite markers in the Peruvian Amazon, offering evidence-based recommendations for panel selection in endemic settings.

Accessibility extends beyond cost savings to physical location. Adegbola and colleagues applied portable Oxford Nanopore sequencing to characterize drug-resistance loci within an antenatal-care population in Nigeria, demonstrating how decentralized platforms can lower the barrier to in-country genotyping and embed genomic analysis in routine clinical touchpoints. The technical significance is considerable: nanopore sequencers are compact, relatively inexpensive, and can operate outside well-resourced reference laboratories, meaning that resistance profiling no longer depends on shipping samples across continents. On the vector side, Boddé and colleagues demonstrate improved species assignment across the entire Anopheles genus using a targeted-sequencing assay for mosquito genotyping paired with updated reference databases, a critical advance given that accurate vector identification underpins every entomological intervention from bed nets to larval source management.

The second theme of the collection is translation: turning genomic data into programmatically actionable outputs that resolve transmission dynamics and parasite connectivity. Pereus and colleagues evaluated P. falciparum diversity across mainland Tanzania using genetic metrics of complexity of infection, parasite connectivity, and transmission intensity, revealing heterogeneity that conventional indicators such as case counts and prevalence surveys can miss. In malaria-endemic regions, transmission is often intensely focal, with hotspots and residual pockets persisting even as overall burden falls, and genomic signatures can pinpoint these pockets with a resolution that routine surveillance cannot match.

That sensitivity to changing dynamics is equally valuable for Plasmodium vivax, the stubborn relapsing parasite that poses unique elimination challenges. Fola and colleagues used population genetic metrics to track P. vivax transmission indicators through a period of transmission decline and subsequent rebound in two endemic areas of Papua New Guinea, showing that genomic signals can capture changing transmission dynamics precisely where they are hardest to measure by conventional means. As countries push toward elimination and case numbers dwindle, traditional metrics lose statistical power; genetic relatedness among the few remaining infections becomes one of the few reliable signals of whether transmission is truly interrupted or quietly continuing.

Perhaps the most consequential use case is antimalarial drug resistance, which remains one of the greatest threats to malaria control globally. Kattenberg and colleagues used genetic surveillance to document the spread of artemisinin-combination-therapy resistance during a period of malaria decline in Vietnam between 2018 and 2020, producing outputs with immediate implications for treatment guidelines and containment efforts. The finding illustrates the operational value of molecular surveillance: when resistance genotypes are mapped in near real time, national programs can adjust first-line therapies, target containment measures to affected regions, and anticipate further spread before it overwhelms treatment policy. The Oxford Nanopore-based profiling of crt, dhfr, and dhps resistance markers in pregnant women reported by Adegbola and colleagues points toward new approaches for embedding resistance genotyping into existing clinical infrastructure such as antenatal care, where pregnant women already receive routine screening and treatment.

Yet real gaps remain between capability and routine use. Safarpour and colleagues synthesized the challenge for one critical elimination use case: distinguishing imported from locally acquired infections. They found that current methods are still limited by cost, by an inability to reliably discriminate between imported and local parasites, by difficulties tracking parasite movement across borders and at within-country or smaller spatial scales, and by reliance on cross-sectional summary statistics that capture only snapshots of transmission rather than its continuous evolution. Their review also highlights a persistent neglect of P. vivax and other non-falciparum species. While P. falciparum accounts for the major burden of global malaria cases, eradication will require concerted efforts to address the unique biology of the relapsing, dormant-liver-stage parasites that characterize vivax malaria.

Encouragingly, several contributions reflect expanding sequencing and bioinformatics capacity, along with growing scientific leadership, within malaria-endemic regions themselves. Investments in regional sequencing hubs, local expertise, and collaborative research networks are enabling countries to generate and interpret genomic data relevant to their own public health priorities rather than exporting samples and analysis abroad. The editors stress that this momentum must be sustained if molecular surveillance is to become routine public health practice rather than remain constrained to research. The next phase, they argue, should focus on generating fit-for-purpose data at the scale and timeliness necessary for translation into decision-making, which will require sustained investment in local infrastructure, harmonized and tailored analytical frameworks, and closer engagement between genomic scientists and national programs.

The editors also emphasize that the future of malaria genomics lies in integration: combining parasite and vector data, and layering molecular, epidemiological, clinical, and environmental information into a coherent picture of transmission. As national programs confront evolving biological and operational challenges, from drug resistance to climate-driven shifts in vector ranges, genetic data will play an increasingly central role in guiding interventions, informing policy, and sustaining progress toward elimination. The collection stands as both a technical benchmark and a roadmap, showing that the tools for genome-informed malaria elimination largely exist, and that the decisive work ahead is making them routine, equitable, and fast enough for the programs that depend on them.

Subject of Research: Malaria molecular surveillance and genomics

Article Title: Editorial: Advanced genetic and genomic methods and applications for malaria surveillance

Article References: Ruybal-Pesántez, S., Kattenberg, J. H., Ghansah, A., & Auburn, S. (2026). Editorial: Advanced genetic and genomic methods and applications for malaria surveillance. Frontiers in Genetics, 17, Article 2000967. https://doi.org/10.3389/fgene.2026.2000967

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.2000967

Keywords: malaria, genomics, molecular surveillance, drug resistance, Plasmodium falciparum, Plasmodium vivax, Anopheles, public health, Editorial, Advanced, genetic, genomic